Universal American Corporation

UAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UAM stands at 0. In comparison, UNH has a market cap of 255.4B. Regarding current trading prices, UAM is priced at $1.75, while UNH trades at $281.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UAM currently has a P/E ratio of N/A, whereas UNH's P/E ratio is 21.27. In terms of profitability, UAM's ROE is +0.17%, compared to UNH's ROE of +0.13%. Regarding short-term risk, UAM is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for UAM.Check UNH's competition here

UAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UAM stands at 0. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, UAM is priced at $1.75, while ANTM trades at $482.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UAM currently has a P/E ratio of N/A, whereas ANTM's P/E ratio is 18.99. In terms of profitability, UAM's ROE is +0.17%, compared to ANTM's ROE of +0.13%. Regarding short-term risk, UAM is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for UAM.Check ANTM's competition here

UAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UAM stands at 0. In comparison, CVS has a market cap of 93.2B. Regarding current trading prices, UAM is priced at $1.75, while CVS trades at $73.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UAM currently has a P/E ratio of N/A, whereas CVS's P/E ratio is 52.71. In terms of profitability, UAM's ROE is +0.17%, compared to CVS's ROE of +0.02%. Regarding short-term risk, UAM is less volatile compared to CVS. This indicates potentially lower risk in terms of short-term price fluctuations for UAM.Check CVS's competition here

UAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UAM stands at 0. In comparison, CI has a market cap of 73.6B. Regarding current trading prices, UAM is priced at $1.75, while CI trades at $275.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UAM currently has a P/E ratio of N/A, whereas CI's P/E ratio is 12.44. In terms of profitability, UAM's ROE is +0.17%, compared to CI's ROE of +0.15%. Regarding short-term risk, UAM is less volatile compared to CI. This indicates potentially lower risk in terms of short-term price fluctuations for UAM.Check CI's competition here

UAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UAM stands at 0. In comparison, ELV has a market cap of 66.8B. Regarding current trading prices, UAM is priced at $1.75, while ELV trades at $302.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UAM currently has a P/E ratio of N/A, whereas ELV's P/E ratio is 12.01. In terms of profitability, UAM's ROE is +0.17%, compared to ELV's ROE of +0.13%. Regarding short-term risk, UAM is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for UAM.Check ELV's competition here

UAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UAM stands at 0. In comparison, HUM has a market cap of 22B. Regarding current trading prices, UAM is priced at $1.75, while HUM trades at $182.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UAM currently has a P/E ratio of N/A, whereas HUM's P/E ratio is 18.59. In terms of profitability, UAM's ROE is +0.17%, compared to HUM's ROE of +0.07%. Regarding short-term risk, UAM is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for UAM.Check HUM's competition here

UAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UAM stands at 0. In comparison, CNC has a market cap of 17.4B. Regarding current trading prices, UAM is priced at $1.75, while CNC trades at $35.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UAM currently has a P/E ratio of N/A, whereas CNC's P/E ratio is -2.62. In terms of profitability, UAM's ROE is +0.17%, compared to CNC's ROE of -0.28%. Regarding short-term risk, UAM is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for UAM.Check CNC's competition here

UAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UAM stands at 0. In comparison, MOH has a market cap of 7.4B. Regarding current trading prices, UAM is priced at $1.75, while MOH trades at $143.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UAM currently has a P/E ratio of N/A, whereas MOH's P/E ratio is 16.07. In terms of profitability, UAM's ROE is +0.17%, compared to MOH's ROE of +0.11%. Regarding short-term risk, UAM is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for UAM.Check MOH's competition here

UAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UAM stands at 0. In comparison, ALHC has a market cap of 3.8B. Regarding current trading prices, UAM is priced at $1.75, while ALHC trades at $18.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UAM currently has a P/E ratio of N/A, whereas ALHC's P/E ratio is -169.73. In terms of profitability, UAM's ROE is +0.17%, compared to ALHC's ROE of -0.00%. Regarding short-term risk, UAM is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for UAM.Check ALHC's competition here

UAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UAM stands at 0. In comparison, OSCR has a market cap of 3.3B. Regarding current trading prices, UAM is priced at $1.75, while OSCR trades at $12.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UAM currently has a P/E ratio of N/A, whereas OSCR's P/E ratio is -7.55. In terms of profitability, UAM's ROE is +0.17%, compared to OSCR's ROE of -0.39%. Regarding short-term risk, UAM is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for UAM.Check OSCR's competition here

UAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UAM stands at 0. In comparison, CLOV has a market cap of 957.4M. Regarding current trading prices, UAM is priced at $1.75, while CLOV trades at $1.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UAM currently has a P/E ratio of N/A, whereas CLOV's P/E ratio is -11.00. In terms of profitability, UAM's ROE is +0.17%, compared to CLOV's ROE of -0.26%. Regarding short-term risk, UAM is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for UAM.Check CLOV's competition here

UAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UAM stands at 0. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, UAM is priced at $1.75, while BHG trades at $16.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UAM currently has a P/E ratio of N/A, whereas BHG's P/E ratio is -0.12. In terms of profitability, UAM's ROE is +0.17%, compared to BHG's ROE of -0.70%. Regarding short-term risk, UAM is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for UAM.Check BHG's competition here

UAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UAM stands at 0. In comparison, CABR has a market cap of 18M. Regarding current trading prices, UAM is priced at $1.75, while CABR trades at $1.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UAM currently has a P/E ratio of N/A, whereas CABR's P/E ratio is -2.65. In terms of profitability, UAM's ROE is +0.17%, compared to CABR's ROE of N/A. Regarding short-term risk, UAM is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for UAM.Check CABR's competition here

UAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UAM stands at 0. In comparison, BMGL has a market cap of 11.3M. Regarding current trading prices, UAM is priced at $1.75, while BMGL trades at $0.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UAM currently has a P/E ratio of N/A, whereas BMGL's P/E ratio is -1.36. In terms of profitability, UAM's ROE is +0.17%, compared to BMGL's ROE of -1.95%. Regarding short-term risk, UAM is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for UAM.Check BMGL's competition here

UAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UAM stands at 0. In comparison, MRAI has a market cap of 4.2M. Regarding current trading prices, UAM is priced at $1.75, while MRAI trades at $0.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UAM currently has a P/E ratio of N/A, whereas MRAI's P/E ratio is -0.08. In terms of profitability, UAM's ROE is +0.17%, compared to MRAI's ROE of +0.52%. Regarding short-term risk, UAM is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for UAM.Check MRAI's competition here

UAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UAM stands at 0. In comparison, NIVF has a market cap of 1.2M. Regarding current trading prices, UAM is priced at $1.75, while NIVF trades at $2.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UAM currently has a P/E ratio of N/A, whereas NIVF's P/E ratio is 0.06. In terms of profitability, UAM's ROE is +0.17%, compared to NIVF's ROE of +1.17%. Regarding short-term risk, UAM is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for UAM.Check NIVF's competition here

UAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UAM stands at 0. In comparison, MGLN has a market cap of 0. Regarding current trading prices, UAM is priced at $1.75, while MGLN trades at $94.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UAM currently has a P/E ratio of N/A, whereas MGLN's P/E ratio is 8.49. In terms of profitability, UAM's ROE is +0.17%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, UAM and MGLN have similar daily volatility (0.00).Check MGLN's competition here

UAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UAM stands at 0. In comparison, AET has a market cap of 0. Regarding current trading prices, UAM is priced at $1.75, while AET trades at $106.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UAM currently has a P/E ratio of N/A, whereas AET's P/E ratio is N/A. In terms of profitability, UAM's ROE is +0.17%, compared to AET's ROE of +0.11%. Regarding short-term risk, UAM and AET have similar daily volatility (0.00).Check AET's competition here

UAM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, UAM stands at 0. In comparison, GTS has a market cap of 0. Regarding current trading prices, UAM is priced at $1.75, while GTS trades at $35.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

UAM currently has a P/E ratio of N/A, whereas GTS's P/E ratio is 10.41. In terms of profitability, UAM's ROE is +0.17%, compared to GTS's ROE of +0.07%. Regarding short-term risk, UAM is less volatile compared to GTS. This indicates potentially lower risk in terms of short-term price fluctuations for UAM.Check GTS's competition here